SCHEMBL20043429

SCHEMBL20043429

CN(C)Cc1cncc(Cl)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.40
PDCD1 Q15116 2/20 0.35
CD274 Q9NZQ7 2/20 0.35
CHRNB2 P17787 2/20 0.34
CHRNA4 P43681 2/20 0.34
POLB P06746 1/20 0.34
NOTUM Q6P988 1/20 0.33
CYP2A6 P11509 1/20 0.32
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
HTR1A P08908 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31721304 1.00 CDK2 (0.40) CDK2PDCD1CD274CHRNB2CHRNA4
SCHEMBL18157909 0.84 CHRNB2 (0.40) CHRNB2CHRNA4POLBNOTUMCYP2A6
SCHEMBL21087425 0.77 CYP2D6 (0.40) CHRNB2CHRNA4CYP2A6ALDH1A1KDM4E
SCHEMBL8436293 0.76 CDK2 (0.38) CDK2HTR2A
SCHEMBL8190613 0.76
SCHEMBL19510964 0.75 CDK2 (0.40) CDK2ALDH1A1KDM4EMEN1CYP1A2
SCHEMBL22772487 0.73
SCHEMBL21899343 0.72 CDK2 (0.41) CDK2NOTUMALDH1A1KDM4EMEN1
SCHEMBL22576285 0.72 CDK2 (0.41) CDK2POLBALDH1A1KDM4EMEN1
SCHEMBL22657003 0.72 MEN1 (0.35) CDK2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190276478-A1 HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC 2019-09-12 US disclosed
WO-2018067762-A2 HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2018-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276478-A1 HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS FNTB, CYP2F1, SDHB CDK2 3341/4885PDCD1 3162/4885CD274 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.